RU2014134409A - Конъюгаты этопозида и доксорубицина для доставки лекарственных средств - Google Patents
Конъюгаты этопозида и доксорубицина для доставки лекарственных средств Download PDFInfo
- Publication number
- RU2014134409A RU2014134409A RU2014134409A RU2014134409A RU2014134409A RU 2014134409 A RU2014134409 A RU 2014134409A RU 2014134409 A RU2014134409 A RU 2014134409A RU 2014134409 A RU2014134409 A RU 2014134409A RU 2014134409 A RU2014134409 A RU 2014134409A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- crr
- alkyl
- therapeutic agent
- independently
- Prior art date
Links
- 0 CC[C@@](C)NCCCCC(C(**NC(CCCCN)C(*(C)C)=O)=O)N** Chemical compound CC[C@@](C)NCCCCC(C(**NC(CCCCN)C(*(C)C)=O)=O)N** 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Соединение, имеющее структуру,где Y представляет собой гидролизуемый линкер;или его фармацевтически приемлемая соль.2. Соединение по п. 1, где Y имеет структуру:где каждый G и G′ представляет собой, независимо, -С(O)-, -С(O)O-, -ОС(O)-, -S(O)O-, -OS(O)-, -S(O)NH-, -NHS(O)-, или -OP(O)(OR)O-;X представляет собой -(необязательно замещенный арил)-, -(CRR)-, -O{(CRR)O}-, -{(CRR)O(CRR)}-, или -(CRR)R(CRR)-;каждый n, о, и р представляет собой, независимо, 1, 2, 3, 4, 5, 6, 7, 8, 9, или 10;Rпредставляет собой Н или Cалкил;Rи Rкаждый независимо выбран из Н, ОН, или Cалкила; иRпредставляет собой О, NH, N(Cалкил), или -необязательно замещенный арил.3. Соединение по п. 2, где G представляет собой -С(O)-.4. Соединение по п. 2 или 3, где G′ представляет собой -С(O)-.5. Соединение по п. 2, где Х представляет собой -(CRR)-.6. Соединение по п. 5, где n представляет собой 1, 2, 3, 4, 5 или 6.7. Соединение по п. 6, где n представляет собой 2 или 3.8. Соединение по п. 7, где n представляет собой 3.9. Фармацевтическая композиция, содержащая соединение по любому из п.п. 1-8 и фармацевтически приемлемый носитель.10. Способ лечения рака, включающий введение пациенту терапевтически эффективного количества соединения по любому из пп. 1-8 или фармацевтической композиции по п. 9.11. Способ по п. 10, дополнительно включающий введение второго терапевтического агента.12. Способ по п. 11, где второй терапевтический агент представляет собой полипептид, включающий последовательность Angiopep-2 (SEQ ID NO:97), и где Angiopep-2 конъюгирован с противораковым агентом.13. Способ по п. 12, где противораковый агент представляет собой паклитаксел.14. Способ по п. 13, где второй терапевтический агент представляет собой ANG1005, имеющий следующую структуру:.
Claims (14)
2. Соединение по п. 1, где Y имеет структуру:
где каждый G и G′ представляет собой, независимо, -С(O)-, -С(O)O-, -ОС(O)-, -S(O)2O-, -OS(O)2-, -S(O)2NH-, -NHS(O)2-, или -OP(O)(OR11)O-;
X представляет собой -(необязательно замещенный арил)-, -(CR12R13)n-, -O{(CR12R13)2O}n-, -{(CR12R13)2O(CR12R13)2}n-, или -(CR12R13)oR14(CR12R13)p-;
каждый n, о, и р представляет собой, независимо, 1, 2, 3, 4, 5, 6, 7, 8, 9, или 10;
R11 представляет собой Н или C1-6 алкил;
R12 и R13 каждый независимо выбран из Н, ОН, или C1-6 алкила; и
R14 представляет собой О, NH, N(C1-6 алкил), или -необязательно замещенный арил.
3. Соединение по п. 2, где G представляет собой -С(O)-.
4. Соединение по п. 2 или 3, где G′ представляет собой -С(O)-.
5. Соединение по п. 2, где Х представляет собой -(CR12R13)n-.
6. Соединение по п. 5, где n представляет собой 1, 2, 3, 4, 5 или 6.
7. Соединение по п. 6, где n представляет собой 2 или 3.
8. Соединение по п. 7, где n представляет собой 3.
9. Фармацевтическая композиция, содержащая соединение по любому из п.п. 1-8 и фармацевтически приемлемый носитель.
10. Способ лечения рака, включающий введение пациенту терапевтически эффективного количества соединения по любому из пп. 1-8 или фармацевтической композиции по п. 9.
11. Способ по п. 10, дополнительно включающий введение второго терапевтического агента.
12. Способ по п. 11, где второй терапевтический агент представляет собой полипептид, включающий последовательность Angiopep-2 (SEQ ID NO:97), и где Angiopep-2 конъюгирован с противораковым агентом.
13. Способ по п. 12, где противораковый агент представляет собой паклитаксел.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10565408P | 2008-10-15 | 2008-10-15 | |
US61/105,654 | 2008-10-15 | ||
US17101009P | 2009-04-20 | 2009-04-20 | |
US61/171,010 | 2009-04-20 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011118055/04A Division RU2531591C2 (ru) | 2008-10-15 | 2009-10-15 | Конъюгаты этопозида и доксорубицина для доставки лекарственных средств |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2014134409A true RU2014134409A (ru) | 2016-03-20 |
Family
ID=42106173
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011118055/04A RU2531591C2 (ru) | 2008-10-15 | 2009-10-15 | Конъюгаты этопозида и доксорубицина для доставки лекарственных средств |
RU2014134409A RU2014134409A (ru) | 2008-10-15 | 2014-08-22 | Конъюгаты этопозида и доксорубицина для доставки лекарственных средств |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011118055/04A RU2531591C2 (ru) | 2008-10-15 | 2009-10-15 | Конъюгаты этопозида и доксорубицина для доставки лекарственных средств |
Country Status (11)
Country | Link |
---|---|
US (3) | US8828925B2 (ru) |
EP (1) | EP2346896A4 (ru) |
JP (1) | JP5705118B2 (ru) |
CN (1) | CN102245636A (ru) |
AU (1) | AU2009304505A1 (ru) |
BR (1) | BRPI0920121A2 (ru) |
CA (1) | CA2740317A1 (ru) |
MX (1) | MX2011004019A (ru) |
RU (2) | RU2531591C2 (ru) |
WO (1) | WO2010043049A1 (ru) |
ZA (1) | ZA201103043B (ru) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1583562T3 (da) | 2003-01-06 | 2011-09-19 | Angiochem Inc | Angiopep-1, beslægtede forbindelser og anvendelser deraf |
ES2383901T5 (es) | 2005-02-18 | 2015-02-25 | Angiochem Inc. | Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro |
US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
ES2424242T3 (es) | 2005-07-15 | 2013-09-30 | Angiochem Inc. | Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos |
EP2074142A4 (en) | 2006-10-19 | 2010-10-27 | Angiochem Inc | COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
BRPI0920209A2 (pt) | 2008-10-15 | 2015-12-22 | Angiochem Inc | conjugados de agonistas de glp-1 e usos dos mesmos |
RU2531591C2 (ru) | 2008-10-15 | 2014-10-20 | Ангиокем Инк. | Конъюгаты этопозида и доксорубицина для доставки лекарственных средств |
US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
MX2011006685A (es) | 2008-12-17 | 2011-09-27 | Angiochem Inc | Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos. |
ES2729261T3 (es) | 2009-04-20 | 2019-10-31 | Angiochem Inc | Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2 |
IN2012DN00248A (ru) | 2009-07-02 | 2015-05-01 | Angiochem Inc | |
EP2885318A4 (en) | 2012-08-14 | 2016-03-30 | Angiochem Inc | PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF |
CA2894548C (en) * | 2012-12-13 | 2021-01-12 | Cytrx Corporation | Anthracycline formulations |
NZ631022A (en) | 2013-06-05 | 2018-05-25 | Cytrx Corp | Cytotoxic agents for the treatment of cancer |
ES2826827T3 (es) * | 2015-06-15 | 2021-05-19 | Angiochem Inc | Métodos para el tratamiento de carcinomatosis leptomeníngea |
CN111718395B (zh) * | 2019-03-21 | 2022-03-18 | 国家纳米科学中心 | 一种前药激活化合物、前药体系及其制备方法和应用 |
CN110590877B (zh) * | 2019-08-13 | 2021-02-19 | 南开大学 | 连接子,载药连接子、细胞穿透肽偶联药物、抗体偶联药物及其制备方法 |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
Family Cites Families (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4904768A (en) | 1987-08-04 | 1990-02-27 | Bristol-Myers Company | Epipodophyllotoxin glucoside 4'-phosphate derivatives |
GB2208511A (en) | 1987-08-07 | 1989-04-05 | Bayer Ag | Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology |
US4942184A (en) | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
US5632990A (en) | 1988-04-22 | 1997-05-27 | Cancer Research Campaign Tech. Ltd. | Treatment for tumors comprising conjugated antibody A5B7 and a prodrug |
US5258499A (en) | 1988-05-16 | 1993-11-02 | Vestar, Inc. | Liposome targeting using receptor specific ligands |
US5028697A (en) | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5948634A (en) | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
DE3912638A1 (de) | 1989-04-18 | 1990-10-31 | Bayer Ag | Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel |
US5126249A (en) | 1989-05-09 | 1992-06-30 | Eli Lilly And Company | Enzymatic removal of a protein amino-terminal sequence |
US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
US6475781B1 (en) | 1990-05-17 | 2002-11-05 | Dana-Farber Cancer Institute, Inc. | Trans-dominant suppressor genes for oligomeric proteins |
GB9017008D0 (en) | 1990-08-02 | 1990-09-19 | Erba Carlo Spa | Process for the enzymatic preparation of basic fibroblast growth factor |
US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
US6495513B1 (en) | 1991-03-11 | 2002-12-17 | Curis, Inc. | Morphogen-enhanced survival and repair of neural cells |
US5955444A (en) | 1991-08-09 | 1999-09-21 | Massachusetts Institute Of Technology | Method of inhibiting abnormal tau hyper phosphorylation in a cell |
US5627270A (en) | 1991-12-13 | 1997-05-06 | Trustees Of Princeton University | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
US5204354A (en) | 1992-02-14 | 1993-04-20 | Merck & Co., Inc. | Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders |
GB9213077D0 (en) | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
EP0671944A4 (en) | 1992-09-25 | 1996-07-24 | Corvas Int Inc | TISSUE VIA-THROMBOPLASTIN FACTOR COMPLEX INHIBITORS DERIVED FROM A BOVINE PANCREATIC TRYPSIN INHIBITOR. |
EP0599303A3 (en) | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide conjugate |
WO1994019692A1 (en) | 1993-02-18 | 1994-09-01 | The General Hospital Corporation | Alzheimer's disease therapeutics |
ZA963619B (en) | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
US5780265A (en) | 1995-06-05 | 1998-07-14 | Genentech, Inc. | Kunitz type plasma kallikrein inhibitors |
US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
IL126115A (en) | 1996-03-11 | 2007-03-08 | Aerovance Inc | Significantly purified protein with suppressive activity for sirin protease and its pharmaceutical preparations |
DE19636889A1 (de) | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
EP0932390A1 (en) | 1996-10-11 | 1999-08-04 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
US5948750A (en) | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
AU6682598A (en) | 1997-03-04 | 1998-09-22 | Bio-Technology General Corporation | Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs |
GB9705903D0 (en) | 1997-03-21 | 1997-05-07 | Elliott Gillian D | VP22 Proteins and uses thereof |
US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
BR9809138A (pt) | 1997-05-21 | 2001-08-28 | Trustees For The Leland Stanfo | Conjugado e método para aumentar o transporte de um composto selecionado atravessando uma membrana biológica |
US6391305B1 (en) | 1997-09-10 | 2002-05-21 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US6093692A (en) | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
US6475481B2 (en) | 1997-11-18 | 2002-11-05 | Canji Inc | Purging of stem cell products |
WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
US5981564A (en) | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
US5922754A (en) | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
WO2000050059A1 (en) | 1999-02-24 | 2000-08-31 | The Uab Research Foundation | Taxane derivatives for targeted therapy of cancer |
US6180607B1 (en) | 1999-08-05 | 2001-01-30 | Christopher Davies | Protein having proteinase inhibitor activity |
US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
EP1214292B1 (en) | 1999-09-24 | 2007-06-13 | Genentech, Inc. | Tyrosine derivatives |
DE19953696A1 (de) | 1999-11-09 | 2001-05-10 | Alexander Cherkasky | Selektive proteolytische Synzyme (SPS) |
AU2001285020A1 (en) * | 2000-08-17 | 2002-02-25 | Synapse Technologies, Inc. | P97-active agent conjugates and their methods of use |
AU2002254400B2 (en) | 2001-03-23 | 2007-08-09 | Napro Biotherapeutics, Inc. | Molecular conjugates for use in treatment of cancer |
US20030170891A1 (en) | 2001-06-06 | 2003-09-11 | Mcswiggen James A. | RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
EP2147679B1 (en) | 2001-07-25 | 2014-06-25 | Raptor Pharmaceutical, Inc. | Compositions for blood-brain barrier transport |
US20040161776A1 (en) | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
US7192921B2 (en) | 2001-11-08 | 2007-03-20 | The Burnham Institute | Peptides that home to tumor lymphatic vasculature and methods of using same |
CA2474283A1 (en) | 2002-02-07 | 2003-08-14 | Yissum Research Development Company Of The Hebrew University In Jerusale M | Amino acid sequences capable of facilitating penetration across a biological barrier |
EP1495045B1 (en) | 2002-03-29 | 2009-09-02 | Creagene, Inc. | Cytoplasmic transduction peptides and uses thereof |
US6881829B2 (en) | 2002-04-26 | 2005-04-19 | Chimeracom, L.L.C. | Chimeric hybrid analgesics |
EP1539208A2 (en) | 2002-06-28 | 2005-06-15 | Nastech Pharmaceutical Company Inc. | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
AU2003295600A1 (en) | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US7319090B2 (en) | 2002-11-27 | 2008-01-15 | University Of North Carolina At Chapel Hill | Methods of treating cerebral ischemia |
US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
US20040102369A1 (en) | 2002-11-27 | 2004-05-27 | The Regents Of The University Of California | Transport of basic fibroblast growth factor across the blood brain barrier |
DK1583562T3 (da) | 2003-01-06 | 2011-09-19 | Angiochem Inc | Angiopep-1, beslægtede forbindelser og anvendelser deraf |
US20040162284A1 (en) | 2003-02-19 | 2004-08-19 | Harris Herbert W. | Method of lowering body temperature with (S) tofisopam |
EP1615655B1 (en) | 2003-04-08 | 2012-02-22 | Biotempt B.V. | Use of compositions for mucosal and oral administration comprising hcg fragments |
EP1620544B1 (en) | 2003-04-17 | 2018-09-19 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
WO2004108071A2 (en) | 2003-06-05 | 2004-12-16 | Salk Institute For Biological Studies | Targeting polypeptides to the central nervous system |
CA2525236C (en) | 2003-06-20 | 2015-03-24 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
US7927811B2 (en) | 2003-08-08 | 2011-04-19 | Proteus Sciences Co., Ltd. | Polypeptides having brain-localizing activity and uses thereof |
EP1663278A4 (en) | 2003-08-28 | 2009-07-29 | Biorexis Pharmaceutical Corp | EPO MIMETIC PEPTIDES AND FUSION PROTEINS |
US20050058702A1 (en) | 2003-09-17 | 2005-03-17 | Ben-Sasson Shmuel A. | Compositions capable of facilitating penetration across a biological barrier |
US20050208095A1 (en) | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
US7208174B2 (en) | 2003-12-18 | 2007-04-24 | Hoffmann-La Roche Inc. | Liposome compositions |
KR20070039593A (ko) | 2004-07-21 | 2007-04-12 | 암브룩스, 인코포레이티드 | 비천연적으로 코딩된 아미노산을 이용한 생합성 폴리펩티드 |
AU2005266184A1 (en) | 2004-07-26 | 2006-02-02 | Asterion Limited | Linkers |
WO2006039253A2 (en) | 2004-09-29 | 2006-04-13 | Children's Memorial Hospital | Sirna-mediated gene silencing of alpha synuclein |
US9002652B1 (en) | 2005-01-27 | 2015-04-07 | Institute For Systems Biology | Methods for identifying and using organ-specific proteins in blood |
PL1853250T3 (pl) | 2005-02-18 | 2012-03-30 | Abraxis Bioscience Llc | Kombinacje i sposoby podawania środków terapeutycznych oraz terapia skojarzona |
ES2383901T5 (es) * | 2005-02-18 | 2015-02-25 | Angiochem Inc. | Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro |
US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
WO2006108052A2 (en) | 2005-04-06 | 2006-10-12 | Genzyme Corporation | Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting |
EP1888121A2 (en) | 2005-05-12 | 2008-02-20 | Tapestry Pharmaceuticals, Inc. | Anticancer targeted conjugates comprising a succinyl or glutaryl linker |
WO2006138343A2 (en) | 2005-06-14 | 2006-12-28 | Raptor Pharmaceutical Inc. | Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof |
ES2424242T3 (es) * | 2005-07-15 | 2013-09-30 | Angiochem Inc. | Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos |
WO2007012004A2 (en) | 2005-07-19 | 2007-01-25 | The Board Of Trustees Of The University Of Illinois | Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof |
US9062126B2 (en) | 2005-09-16 | 2015-06-23 | Raptor Pharmaceuticals Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof |
US8053569B2 (en) | 2005-10-07 | 2011-11-08 | Armagen Technologies, Inc. | Nucleic acids encoding and methods of producing fusion proteins |
EP2202239A1 (en) | 2005-11-01 | 2010-06-30 | Alnylam Pharmaceuticals Inc. | RNAI inhibition of influenza virus replication |
WO2007053946A1 (en) | 2005-11-09 | 2007-05-18 | Conjuchem Biotechnologies Inc. | Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin |
US8290433B2 (en) | 2007-11-14 | 2012-10-16 | Blaze Mobile, Inc. | Method and system for securing transactions made through a mobile communication device |
AR054215A1 (es) | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
US7477504B1 (en) | 2006-03-13 | 2009-01-13 | C.P.D. Technologies, Inc. | Versatile stun glove |
WO2008100328A2 (en) | 2006-07-13 | 2008-08-21 | Burnham Institute For Medical Research | METHODS AND COMPOSITIONS FOR TARGETING gC1qR/p32 |
EP2074142A4 (en) | 2006-10-19 | 2010-10-27 | Angiochem Inc | COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF |
US9399675B2 (en) | 2007-02-28 | 2016-07-26 | The Board Of Regents Of The University Of Oklahoma | Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration |
US8795627B2 (en) | 2007-03-21 | 2014-08-05 | Raptor Pharmaceuticals Inc. | Treatment of liver disorders by administration of RAP conjugates |
BRPI0809234A2 (pt) | 2007-03-21 | 2014-09-02 | Raptor Pharmaceutical Inc | Peptídeos de proteína associada a receptor (rap) cíclico |
WO2009039188A1 (en) | 2007-09-17 | 2009-03-26 | Ludwig Institute For Cancer Research Ltd | Peptides and methods for the treatment of gliomas and other cancers |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US20110117627A1 (en) | 2008-07-10 | 2011-05-19 | The Board Of Trustees Of The University Of Illinois | Regulation of apoptosis by neural specific splice variants of ig20 |
RU2531591C2 (ru) | 2008-10-15 | 2014-10-20 | Ангиокем Инк. | Конъюгаты этопозида и доксорубицина для доставки лекарственных средств |
US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
MX2011006685A (es) | 2008-12-17 | 2011-09-27 | Angiochem Inc | Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos. |
US20100284921A1 (en) | 2009-05-08 | 2010-11-11 | Temple University - Of The Commonwealth System Of Higher Education | Targeted nanoparticles for intracellular cancer therapy |
US20110111056A1 (en) | 2009-06-03 | 2011-05-12 | Dicerna Pharmaceuticals, Inc. | Peptide dicer substrate agents and methods for their specific inhibition of gene expression |
ES2562463T3 (es) | 2009-07-14 | 2016-03-04 | Mayo Foundation For Medical Education And Research | Administración no covalente, mediada por péptidos, de agentes activos a través de la barrera hematoencefálica |
US8530429B2 (en) | 2009-11-24 | 2013-09-10 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
US9095541B2 (en) | 2009-11-24 | 2015-08-04 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
EP2333074A1 (en) | 2009-12-14 | 2011-06-15 | Robert Steinfeld | Substances and methods for the treatment of lysosmal storage diseases |
CA2789484C (en) | 2010-03-08 | 2019-10-22 | Sloan-Kettering Institute For Cancer Research | Cdc7 kinase inhibitors and uses thereof |
EP2550285B1 (en) | 2010-03-22 | 2017-07-19 | President and Fellows of Harvard College | Trioxacarcins and uses thereof |
WO2011119608A1 (en) | 2010-03-26 | 2011-09-29 | University Of Tennessee Research Foundation | Peptides that specifically target amyloid deposits |
EP2558503B1 (en) | 2010-04-14 | 2015-12-09 | National Research Council of Canada | Compositions and methods for brain delivery of analgesic peptides |
US8218280B2 (en) | 2010-07-08 | 2012-07-10 | Schneider Electric USA, Inc. | Secondary thermal sensor for primary conductors |
EP2601220A2 (en) | 2010-08-06 | 2013-06-12 | U3 Pharma GmbH | Use of her3 binding agents in prostate treatment |
CN102406949B (zh) | 2010-09-21 | 2013-05-29 | 复旦大学 | 一种靶向示踪的多模式诊断纳米影像药物 |
CA2817577A1 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2817250A1 (en) | 2010-11-18 | 2012-05-24 | The General Hospital Corporation | Novel compositions and uses of anti-hypertension agents for cancer therapy |
CN102552928A (zh) | 2010-12-19 | 2012-07-11 | 复旦大学 | 一种治疗脑部肿瘤的双级靶向递药系统及其制备方法 |
KR101875720B1 (ko) | 2011-01-10 | 2018-07-09 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀린온 및 이의 고체 형태의 제조 방법 |
CN102614105A (zh) | 2011-01-28 | 2012-08-01 | 复旦大学 | 一种脑靶向载两性霉素b聚合物胶束给药系统 |
JP2014506922A (ja) | 2011-03-01 | 2014-03-20 | ティーオー − ビービービー ホールディング ベスローテン フェンノートシャップ | 難水溶性物質の高度なアクティブリポソームローディング |
WO2012135025A2 (en) | 2011-03-28 | 2012-10-04 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
WO2012138694A2 (en) | 2011-04-07 | 2012-10-11 | Emory University | Compositions comprising saccharide binding moieties and methods for targeted therapy |
RU2013154422A (ru) | 2011-05-09 | 2015-06-20 | Институт Кимик Де Саррия | Полимерные наночастицы, предназначенные для доставки лекарственных средств |
WO2013004716A1 (en) | 2011-07-04 | 2013-01-10 | Universität Basel | Peptide beads |
KR20140063605A (ko) | 2011-07-19 | 2014-05-27 | 인피니티 파마슈티칼스, 인코포레이티드 | 헤테로사이클릭 화합물 및 그의 용도 |
JP6027610B2 (ja) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環式化合物及びその使用 |
RU2636588C2 (ru) | 2011-08-11 | 2017-11-24 | ИНТЕЛЛАЙКИН, ЭлЭлСи | Полиморфы ингибитора киназы |
AR091790A1 (es) | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | Derivados de isoquinolin-1-ona y sus usos |
WO2013049332A1 (en) | 2011-09-29 | 2013-04-04 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
WO2013056096A1 (en) | 2011-10-13 | 2013-04-18 | Angiochem Inc. | Polypeptide-opioid conjugates and uses thereof |
PE20150041A1 (es) | 2011-10-27 | 2015-01-28 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
US9403820B2 (en) | 2011-11-11 | 2016-08-02 | Intellikine Llc | Kinase inhibitor polymorphs |
CA2857548A1 (en) | 2011-12-01 | 2013-06-06 | Angiochem Inc. | Targeted enzyme compounds and uses thereof |
AU2012344702A1 (en) | 2011-12-01 | 2014-06-19 | Angiochem Inc. | Targeted lysosomal enzyme compounds |
ES2843402T3 (es) | 2011-12-13 | 2021-07-16 | Engeneic Molecular Delivery Pty Ltd | Minicélulas intactas de origen bacteriano para la administración de agentes terapéuticos a tumores cerebrales |
CN104245794A (zh) | 2011-12-16 | 2014-12-24 | 麻省理工学院 | α-氨基脒聚合物及其用途 |
WO2013120107A1 (en) | 2012-02-09 | 2013-08-15 | University Of Rochester | Methods and compositions for treating a subject to inhibit hearing loss |
US20150037281A1 (en) | 2012-03-02 | 2015-02-05 | Icahn School Of Medicine At Mount Sinai | Variants of prothymosin alpha and methods of using same |
CA3152081A1 (en) | 2012-04-04 | 2013-10-10 | Halozyme, Inc. | Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane |
WO2013162757A1 (en) | 2012-04-26 | 2013-10-31 | Yale University | Cytotoxic-drug delivering molecules targeting hiv (cdm-hs), cytotoxic activity against the human immunodeficiency virus and methods of use |
WO2013185235A1 (en) | 2012-06-15 | 2013-12-19 | Angiochem Inc. | Targeted iduronidase compounds |
-
2009
- 2009-10-15 RU RU2011118055/04A patent/RU2531591C2/ru not_active IP Right Cessation
- 2009-10-15 AU AU2009304505A patent/AU2009304505A1/en not_active Abandoned
- 2009-10-15 EP EP09820163.5A patent/EP2346896A4/en not_active Withdrawn
- 2009-10-15 US US13/124,022 patent/US8828925B2/en active Active
- 2009-10-15 JP JP2011531314A patent/JP5705118B2/ja not_active Expired - Fee Related
- 2009-10-15 MX MX2011004019A patent/MX2011004019A/es not_active Application Discontinuation
- 2009-10-15 BR BRPI0920121A patent/BRPI0920121A2/pt not_active IP Right Cessation
- 2009-10-15 CA CA2740317A patent/CA2740317A1/en not_active Abandoned
- 2009-10-15 WO PCT/CA2009/001481 patent/WO2010043049A1/en active Application Filing
- 2009-10-15 CN CN200980150439XA patent/CN102245636A/zh active Pending
-
2011
- 2011-04-21 ZA ZA2011/03043A patent/ZA201103043B/en unknown
-
2014
- 2014-07-11 US US14/329,803 patent/US20150038429A1/en not_active Abandoned
- 2014-08-22 RU RU2014134409A patent/RU2014134409A/ru not_active Application Discontinuation
-
2016
- 2016-09-12 US US15/262,909 patent/US20160375145A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US8828925B2 (en) | 2014-09-09 |
ZA201103043B (en) | 2012-07-25 |
CN102245636A (zh) | 2011-11-16 |
AU2009304505A1 (en) | 2010-04-22 |
RU2531591C2 (ru) | 2014-10-20 |
MX2011004019A (es) | 2011-06-24 |
JP2012505838A (ja) | 2012-03-08 |
US20150038429A1 (en) | 2015-02-05 |
EP2346896A4 (en) | 2014-06-25 |
US20160375145A1 (en) | 2016-12-29 |
BRPI0920121A2 (pt) | 2019-09-24 |
WO2010043049A1 (en) | 2010-04-22 |
CA2740317A1 (en) | 2010-04-22 |
EP2346896A1 (en) | 2011-07-27 |
US20120135914A1 (en) | 2012-05-31 |
RU2011118055A (ru) | 2012-11-27 |
JP5705118B2 (ja) | 2015-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2014134409A (ru) | Конъюгаты этопозида и доксорубицина для доставки лекарственных средств | |
JP2020508310A5 (ru) | ||
ES2754549T3 (es) | Inhibidores heterobifuncionales de E-selectinas y receptores de quimioquinas CXCR4 | |
JP2006523216A5 (ru) | ||
Deshmukh et al. | A series of α-amino acid ester prodrugs of camptothecin: in vitro hydrolysis and A549 human lung carcinoma cell cytotoxicity | |
JP2012505838A5 (ru) | ||
JP2011521940A5 (ru) | ||
JP2008536807A5 (ru) | ||
JP2017518302A5 (ru) | ||
JP2019504100A5 (ru) | ||
US20170296566A9 (en) | Methods and compositions for treating and/or preventing mucositis | |
JP2015512953A5 (ru) | ||
JP2020508985A5 (ru) | ||
US10953099B2 (en) | Compositions comprising a metal source, dithiocarbamate and cyclodextrin | |
US11987647B2 (en) | Cyclic cell-penetrating peptides with one or more hydrophobic residues | |
JP2012506872A5 (ru) | ||
RU2016144668A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
JP2018507844A (ja) | 抗体薬物コンジュゲート | |
JP2013509411A5 (ru) | ||
JP2011505371A5 (ru) | ||
CA3149641A1 (en) | Lipidated cationic peptide-peg compositions for nucleic acid delivery | |
JP2018527360A5 (ru) | ||
US20230073036A1 (en) | Polyethylene glycol conjugate drug, preparation method therefor and application thereof | |
WO2005014032A3 (en) | Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite | |
JP2007523123A5 (ru) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20170823 |